Evidence map›Paper›PMID 37079368›Full record

ArticleeLife2023

Common genetic variations in telomere length genes and lung cancer: a Mendelian randomisation study and its novel application in lung tumour transcriptome.

Ricardo Cortez Cardoso Penha, Karl Smith-Byrne, Joshua R Atkins, Philip C Haycock, Siddhartha Kar, Veryan Codd, Nilesh J Samani, Christopher Nelson, Maja Milojevic, Aurélie A G Gabriel and 5 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 5 countries.

Ricardo Cortez Cardoso PenhaGenomic Epidemiology branch, International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France.ORCID 0000-0002-2847-1993
Karl Smith-ByrneCancer Epidemiology Unit, University of Oxford, Oxford, United Kingdom.
Joshua R AtkinsGenomic Epidemiology branch, International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France.
Philip C HaycockMRC Integrative Epidemiology Unit, Bristol Population Health Science Institute, Bristol Medical School (PHS), Bristol, United Kingdom.ORCID 0000-0001-5001-3350
Siddhartha KarMRC Integrative Epidemiology Unit, Bristol Population Health Science Institute, Bristol Medical School (PHS), Bristol, United Kingdom.
Veryan CoddDepartment of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
Nilesh J SamaniDepartment of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
Christopher NelsonDepartment of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.
Maja MilojevicGenomic Epidemiology branch, International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France.
Aurélie A G GabrielLudwig Lausanne Branch, Faculty of Biology and Medicine, Lausanne, Switzerland.
Christopher AmosInstitute for Clinical and Translational Research, Baylor College of Medicine, Houston, United States.
Paul BrennanGenomic Epidemiology branch, International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France.
Rayjean J HungLunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Canada.
Linda KachuriDepartament of Epidemiology and Population Health, Stanford University, Stanford, United States.
James D MckayGenomic Epidemiology branch, International Agency for Research on Cancer/World Health Organization (IARC/WHO), Lyon, France.ORCID 0000-0002-1787-3874
World Health Organization · CHUniversity of Leicester · GBMRC Integrative Epidemiology UnitBaylor College of Medicine · USLunenfeld-Tanenbaum Research Institute · CAStanford University · USTranslational Genomics Research Institute · USUniversity of Oxford · GB

Funding

Translating Molecular and Clinical Data to Population Lung Cancer Risk AssessmentU19CA203654 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Christopher I. Amos, Rayjean J. Hung · 2017 to 2026
$23.7M
Comprehensive Investigation of Multiple Myeloma Genetic Susceptibility in African AmericansK99CA246076 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KACHURI, MIRLINDA · 2020 to 2021
$258k
Cancer Research UK 29017Cancer Research UK 29019Cancer Research UK C18281/A29019NCI NIH HHS K99 CA246076NCI NIH HHS U19 CA203654World Health Organization 001
6 · The paper itself

Abstract

Background: Genome-wide association studies (GWASs) have identified genetic susceptibility variants for both leukocyte telomere length (LTL) and lung cancer susceptibility. Our study aims to explore the shared genetic basis between these traits and investigate their impact on somatic environment of lung tumours. Methods: We performed genetic correlation, Mendelian randomisation (MR), and colocalisation analyses using the largest available GWASs summary statistics of LTL (N=464,716) and lung cancer (N=29,239 cases and 56,450 controls). Principal components analysis based on RNA-sequencing data was used to summarise gene expression profile in lung adenocarcinoma cases from TCGA (N=343). Results: Although there was no genome-wide genetic correlation between LTL and lung cancer risk, longer LTL conferred an increased risk of lung cancer regardless of smoking status in the MR analyses, particularly for lung adenocarcinoma. Of the 144 LTL genetic instruments, 12 colocalised with lung adenocarcinoma risk and revealed novel susceptibility loci, including Conclusions: This study identified an association between longer genetically predicted LTL and lung cancer and sheds light on the potential molecular mechanisms related to LTL in lung adenocarcinomas. Funding: Institut National du Cancer (GeniLuc2017-1-TABAC-03-CIRC-1-TABAC17-022), INTEGRAL/NIH (5U19CA203654-03), CRUK (C18281/A29019), and Agence Nationale pour la Recherche (ANR-10-INBS-09).

Indexed as

Adenocarcinoma of LungLung NeoplasmsFemaleGenetic VariationGenome-Wide Association StudyHumansLeukocytesMaleRisk FactorsRNA Splicing FactorsTelomereTranscription FactorsTranscriptomePRPF6 protein, humanRNA Splicing FactorsTranscription Factorsepidemiologygene expressionGenome Stabilityglobal healthGWAShumanlung cancerMendelian randomisationtelomere length

Identifiers

PMID37079368
PMCPMC10118386
OpenAlexW4366485637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.